
Azenta (AZTA) Stock Forecast & Price Target
Azenta (AZTA) Analyst Ratings
Bulls say
Azenta is a promising company with a strong future ahead, thanks to its innovative solutions in biological and chemical sample exploration and management. Its two segments, Sample Management Solutions and Multiomics, are both poised for impressive revenue growth in the coming years, leading to stronger margins and profitability. Despite potential headwinds such as increased competition in Multiomics, Azenta's strong market presence in the US and its plans for M&A activities could offset any potential negative impacts. Overall, investors can expect a solid return on investment in this stock.
Bears say
Azenta is expecting organic revenue growth and adjusted EBITDA margin expansion in FY26, driven by improvements in gross margin and opex leverage. Despite challenges in its end-markets, management believes that the company's initiatives in FY25 will support growth and margins. A potential sale of its B Medical business and the upcoming investor day could serve as positive catalysts. However, with the stock currently trading at a premium price, we remain cautious and have a negative outlook on Azenta's stock.
This aggregate rating is based on analysts' research of Azenta and is not a guaranteed prediction by Public.com or investment advice.
Azenta (AZTA) Analyst Forecast & Price Prediction
Start investing in Azenta (AZTA)
Order type
Buy in
Order amount
Est. shares
0 shares